





**Innovation in Paediatric Precision Medicine**

**Seed Funding**

**Application Form**

September 2020

**Contents**

[About Luminesce Alliance 3](#_Toc47955206)

[A. Innovation in Paediatric Precision Medicine Innovation Seed Funding 4](#_Toc47955207)

[1.0 Funding application steps 4](#_Toc47955208)

[2.0 Important Dates 4](#_Toc47955209)

[3.0 Eligibility 4](#_Toc47955210)

[4.0 The Review Panel 5](#_Toc47955211)

[5.0 Terms and Conditions 5](#_Toc47955212)

[B. Application Form 7](#_Toc47955213)

1. [Contact Details 7](#_Toc47955214)
2. [Research Proposal 8](#_Toc47955215)
3. [Signatures 10](#_Toc47955216)

[C. Submission Process 10](#_Toc47955217)

# **About Luminesce Alliance**

|  |  |
| --- | --- |
|  | Luminesce Alliance is a paediatric research hub that galvanises and accelerates NSW led paediatric research, harnessing Partners’ strengths to unlock future prevention, treatments and cures for childhood illnesses. |

Our Vision

Our Vision is to create Australia’s most ground breaking, innovative and translational paediatric research hub that will change children’s health around the world.

Our Mission

Our Mission is to have a voice on a national and international platform so that our research is disseminated and implemented to directly improve the health of children.

Our Purpose

Our Purpose is to empower our partners to work together in changing the global landscape in paediatric research.

Luminesce Alliance works bedside to benchtop to bedside

As an alliance between clinical and research organisations, Luminesce Alliance enables clinicians to drive the research agenda - bedside to benchtop - and for researchers to support rapid clinical translation of their work - benchtop to bedside. Luminesce Alliance provides a working demonstration of translational research in paediatrics.

Luminesce Alliance has critical mass



Our Partners

As an alliance we have access to Australia’s largest and most ethnically diverse paediatric patient population, with the Sydney Children’s Hospitals Network providing care to over 35% of the sickest children in Australia. This critical mass supports the clinical and scientific expertise for examining new models of care, their costs and benefits, and processes of effective integration into our healthcare system.

Luminesce Alliance partners have interlocking and reinforcing specialisations

Luminesce Alliance partners cover a wide range of paediatric health issues, from cancer and rare diseases to orthopaedic surgery and mental health. They also share approaches to healthcare including significant expertise in “omics”, disease modelling, clinical trials, psychosocial impacts; application of new technologies, and, increasingly, a focus on population health, health economics and health services implementation.

# **Innovation in Paediatric Precision Medicine Innovation Seed Funding**

Luminesce Alliance is pleased to offer researchers within the Luminesce Alliance partnership seed funding for innovative paediatric precision medicine research projects. The intentions of these seed funding grants are:

* To initiate innovative and new paediatric precision medicine-based research projects
* To assist these projects to gather evidence and data to seek further funding and/or
* To use this evidence or data as a means to translate precision medicine into the clinical setting

The interpretation of precision medicine and its application to the project proposal is at the discretion of the applicant. The project should ideally be able to commence on the 1st January 2021 with a final report due on the 30th June 2022 (maximum of 18 months). Innovation seed funding is capped at $200,000 per awarded project. $100,000 has also been set aside to fund a health economic/health implementation paediatric precision medicine project. The total funding pool is $1,000,000.

The selection of projects for funding will be based on the merits of the application and its alignment with the intentions of the seed funding and the philosophy of Luminesce Alliance. Applicants are required to review the eligibility criteria, review the terms and conditions and complete and submit the application form before the deadline.

## 1.0 Funding application steps

1. Read the eligibility criteria, note important dates and other information contained in this application document
2. Complete the application form (Section 2.0). **Please note that there are word limits in sections of the application and applicants need to keep within these work limits.**
3. Obtain the appropriate signatures
4. Submit the application by the 30th October 2020 as directed (Section 3.0)

## 2.0 Important Dates

1. Luminesce Alliance Innovation in Precision Medicine Seed Funding Grants opens 15th September 2020
2. Applications must be received by the 30th October 2020
3. Applications will be reviewed by a review panel (if required)
4. Applicants are notified by the 30th November 2020. The decision of the review panel will be final.

## 3.0 Eligibility

To be eligible to submit for a seed funding grant:

* The principal investigator must be employed by of the one of the Luminesce Alliance partners namely:
  + The Sydney Children’s Hospital Network
  + The Children’s Cancer Institute
  + The Children’s Medical Research Institute
  + The University of Sydney
  + The University of New South Wales Sydney
* The project involves precision medicine. The interpretation of precision medicine and how it relates to the project is at the discretion of the applicant.
* The project budget must not exceed $200,000.
* $100,000 has been set aside to fund a health economics/health implementation paediatric precision medicine based project.
* The project must be able to commence on the 1st January 2021 and a final report be submitted by the 30th June 2022. Progress reports will be required every six months.
* If successful, the project must comply with the Terms and Conditions of the Seed Funding Grant

## 4.0 The Review Panel

Luminesce Alliance may convene a review panel depending on the number of the applications received and the amount of funding requested. This will be at the discretion of Luminesce Alliance. Should a review panel be convened, it will include nominated representatives from the Luminesce Alliance partners. It may also include independent representatives outside of the Alliance. Nominated representatives will be asked to declare any conflict of interest prior to any discussion of any application. This includes being a named investigator on the application. They will be excused from any deliberation of that application should they declare a conflict of interest.

1. The application will be given a unique identifier and all contact details of the applicant(s) will be removed. The unique identifier will be used through the review process.
2. Individual review panellist will be asked to review and rank the application based on the following criteria:
   1. The innovative nature of the project
   2. The impact of the application for changing paediatric outcomes
   3. The likelihood that the application will be able produce substantial results with an 18-months period
   4. Whether the results will enable the investigator to seek future funding from other sources e.g. NHMRC
   5. Whether the results can lead to adoption of precision medicine into the clinical setting
   6. The amount of funds requested and its appropriateness
   7. Whether the project should be funded
3. The scores and review of the panel will be collated, and a final score will be tallied
4. The final determination will be based on the final score and the overall total amount requested.

Should a review panel be not be required, the final determination of the grants to be awarded will be made by the Luminesce Alliance Executive Management Committee. Whilst a total of $1,000,000.00 will be made available, the total funds awarded may not exceed this amount. Funding will be awarded based on the merits of the application and not on the total amount available. .

## 5.0 Terms and Conditions

Should the application for funding be successful, the principal investigator needs to accept the following terms and conditions.

1. The principal investigator must be employed by of the one of the Luminesce Alliance partners namely:
   1. The Sydney Children’s Hospital Network
   2. The Children’s Cancer Institute
   3. The Children’s Medical Research Institute
   4. The University of Sydney
   5. The University of New South Wales Sydney
2. The project involves precision medicine. The interpretation of precision medicine and its application to the project proposal is at the discretion of the applicant.
3. The project must be able to commence on the 1st January 2021 and a final report be submitted by 30th June 2022.
4. The project budget must not exceed $200,000.
5. The principal investigator agrees to report on the progress of the study every six months.
6. The principal investigator is required produce any additional information regarding the progress of the study during the term of the funding should it be requested.
7. The principal investigator will be responsible for all aspects of the conduct of the project and must take all necessary steps to ensure that the project is conducted under Good Clinical Practice Guidelines.
8. The principal investigator is responsible for seeking approval from all necessary authorities, including the relevant Institutional Human Research Ethics Committee and institutions for the conduct of the project.
9. The principal investigator agrees that the project will be listed as a Project Schedule under the relevant Master Services Agreement between Luminesce Alliance and the principal investigator’s employer. The project and the investigator would then be required to comply with this Master Services Agreement and the Head Agreement between Luminesce Alliance and NSW Health, which the Master Services Agreement falls under. This includes acknowledge of the funding source through publications and presentations.
10. Funding will be made in two payments, the first upon execution of the Project Schedule and the second after the acceptance of the 1st progress report.
11. Funding may be suspended or cancelled should progress be deemed insufficient or otherwise outlined by the Head Agreement and the relevant Master Services Agreement.

# **Application Form**

## Contact Details

|  |  |
| --- | --- |
| **Principal Investigator**  **(A)** | Name:  Job Title:  Qualification:  Telephone:  Email:  Employer: |
| **Investigator**  **(B)** | Name:  Job Title:  Qualification:  Telephone:  Email:  Employer: |
| **Investigator**  **(C)** | Name:  Job Title:  Qualification:  Telephone:  Email:  Employer: |
| **Investigator**  **(D)** | Name:  Job Title:  Qualification:  Telephone:  Email:  Employer: |
| **Investigator**  **(E)** | Name:  Job Title:  Qualification:  Telephone:  Email:  Employer:  (Please add more lines if required) |

## Research Proposal

|  |
| --- |
| 1.Name of proposed research project |
|  |

|  |
| --- |
| 2.Short name of the project |
|  |

|  |  |
| --- | --- |
| 3.Is this project a health economic/health implementation based research project? | |
| Yes | No |

|  |
| --- |
| 4.Background  *Please describe the problem and the existing evidence to support the research proposal (Max 500 words)* |
|  |

|  |
| --- |
| 5.Aim  *What is the aim(s) of the project? (Max 125 words)* |
|  |

|  |
| --- |
| 6.Hypothesis  *What is the hypothesis of the project? (Max 125 words)* |
|  |

|  |
| --- |
| 7.Innovation  *Why is this research project innovative and new? (Max 250 words)* |
|  |

|  |
| --- |
| 8.Methodology  *Describe how the research project will be conducted? (Max 500 words)* |
|  |

|  |
| --- |
| 9.Project Time  *Please provide a project timeline. Please note that project is to commence in January 2021 and a final report is due in June 2022. Please take these milestones into consideration in developing the timeline. (Max 250 words)* |
|  |

|  |
| --- |
| 10. Outcome  *How will the results of the project be utilised? E.g. used to support a future funding application, used as evidence to change clinical practice, for publications and presentations (Max 250 words)* |
|  |

|  |
| --- |
| 11. In-kind Support and other funding  *Does this proposal have any in-kind support (e.g. use of equipment) and other funding? (Max 125 words)* |
|  |

|  |
| --- |
| 12.Budget |
| |  |  |  | | --- | --- | --- | | Item | Description | $ | | Personnel Cost |  |  | |  |  | |  |  | |  |  | | Direct Research Cost  e.g. Consumables |  |  | |  |  | |  |  | |  |  | |  |  | |  |  | | Other, *please describe* |  |  | |  |  | | Total Amount |  |  | |

## Signatures

|  |  |
| --- | --- |
| Head of Department | I, as Head of Department, support this funding application and will make available the necessary resources for the conduct of this project should it be successful in receiving a Luminesce Alliance Innovation in Precision Medicine Seed Funding Grant  Name:  Department/Institution:  Email:  Signature:  Date: |
| Principal Investigator | I, as the Principal Investigator, have read and understood the eligibility criteria, the funding application process and will be able to accept the terms and conditions of the funding grant should the application be successful.  Name:  Department/Institution:  Email:  Signature:  Date: |

# **Submission Process**

Please prepare the following for submission:

* A Word version of the application form
* A PDF version of the application form

Please electronically submit both documents to:

Mr Quoc Nguyen

Project Manager

Luminesce Alliance

E: [qnguyen@luminesce.org.au](mailto:qnguyen@luminesce.org.au)

The deadline for submission is the **Friday 30th October 2020**